Person:
AKKOÇ, TUNÇ

Loading...
Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

AKKOÇ

First Name

TUNÇ

Name

Search Results

Now showing 1 - 3 of 3
  • Publication
    Lymphocyte proliferation in common variable immunodeficiency (CVID) patients by carboxyfluorescein succinimidyl ester (CFSE)
    (2011-01-01) AKKOÇ, TUNÇ; ÖĞÜLÜR, İSMAİL; AYDINER, ELİF; BARIŞ, SAFA; Izgi A., AKKOÇ T., Ogulur I., Tevetoglu A., AYDINER E., BARIŞ S., Bahceciler N., Barlan I.
    Objective: Common variable immunodeficiency (CVID) is a heterogeneous disease in the group of predominantly antibody deficiencies, which is defined by hypogammaglobulinemia and normal or low level of B cells, and characterized by increased susceptibility to recurrent bacterial infections, autoimmune disorders, and malignancies. In this study, we aimed to investigate the proliferation of the B and T lymphocytes in patients with CVID.
  • PublicationOpen Access
    Investigation of Th17 cell differentiation in immunodeficiencies associated with high IgE levels and/or autoimmunity
    (2011-01-01) AKKOÇ, TUNÇ; ÖĞÜLÜR, İSMAİL; AYDINER, ELİF; BARIŞ, SAFA; AKKOÇ T., Tevetoglu A., Ogulur I., Izgi A., AYDINER E., BARIŞ S., Bahceciler N., Barlan I.
    Objective: Hyper IgE Syndrome (HIES) and Common Variably Immunodeficiency (CVID) are immuno-deficiency diseases. HIES is characterized by recurrent skin abscesses, pneumonia, mucocutaneous fungal infections, eczama, eosinophilia and high serum IgE levels. CVID is characterized by recurrent bacterial infections in airways and gastrointestinal tract. In this study, differentiation of Th17 cells were aimed to be investigated in CVID and HIES patients.
  • PublicationOpen Access
    Th17 differentiation in hyper-IgE syndrome; IL-17 secretion and ROR gamma t expression
    (2013-01-01) AKKOÇ, TUNÇ; ÖĞÜLÜR, İSMAİL; AKKOÇ T., Ogulur I., Tevetoglu A., Izgi A., Hatirnaz-Ng O., Yin-Ng Y., Safa B., Aydiner-Karakoc E.
    Objective: Hyper-IgE syndrome (HIES) is characterized by susceptibility to infection and low number of Th17 cells. Th17 is believed to be critical in the clearance of fungal and extracellular bacterial infections. Present study investigates the differentiation of Th17 cells by evaluation of interleukin 17 (IL-17) secretion and RAR-related orphan receptor gamma t (ROR gamma t) expression in HIES compared with healthy subjects. Objective: Hyper-IgE syndrome (HIES) is characterized by susceptibility to infection and low number of Th17 cells. Th17 is believed to be critical in the clearance of fungal and extracellular bacterial infections. Present study investigates the differentiation of Th17 cells by evaluation of interleukin 17 (IL-17) secretion and RAR-related orphan receptor gamma t (RORγt) expression in HIES compared with healthy subjects. Method: Three children diagnosed with HIES and 4 healthy subjects were enrolled in the study. HIES scores were evaluated and clinical data of patients were collected from their hospital records. At Th17 polarizing conditions, Th17 differentiation was assessed by the secretion of IL-17 with ELISA and the expression of ROR-γt with real time PCR. Results: HIES (n=3) patients showed significantly lower levels of IL-17 secretion compared to the healthy subjects (n=4) regarding the peripheral blood mononuclear cells (PBMCs) and CD45+RA naive T cells cultured in Th17 differentiating conditions. In addition, phorbol 12-myristate 13-acetate (PMA) and ionomycin stimulated IL-17 levels of healthy group were significantly higher than unstimulated conditions. Moreover, PMA and ionomycin stimulated IL-17 levels of PBMC cultures were significantly higher when compared to unstimulated conditions for both HIES patients and healthy subjects. ROR-γt expression level of stimulated PBMCs for HIES patient was detected nearly half of that of the healthy subject. Conclusion: Evaluation of IL-17 secretion and ROR-γt expression should be performed to determine the patients who are candidates for mutation analyses. Performing these steps and selection of HIES patients without known mutations in our country would provide an opportunity to discover new genetic defects and so new therapeutic approaches in HIES